MARKET WIREReuters • 1h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
Why KRMD Stock advanced +0.31% Today — RQD Quant Desk Flash
$3.23 +0.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.23
KORU Medical Systems Inc. (KRMD) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $149.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on KRMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $3.23 (+0.31% 1D, market cap $149.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, KRMD ranks #382 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does KRMD compare to LUNG and SKYA in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $135.9M) and SKYA (SkyAI Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for KRMD?
▼
Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.23 (-0.13%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-4.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRMD)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY KRMD SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (33% of score)
Altman Z-Score 8.05 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 1.1% FCF Margin ($462.4K FCF) & 62.3% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.96+1.4% Next Q
40
Q2 (-2Q)Grade D$3.00+5.7% Next Q
43
Q3 (-1Q)Grade D$3.17+1.9% Next Q
45
CurrentGrade D$3.23-5.6% Hist 90D α
48
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a KRMD Turnaround Squeeze
While KRMD currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Clean SEC annual filing review with no major hidden accounting time-bombs.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.13) and Max Pain ($3.39) forces dealer call-delta covering toward $6.94.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KRMD Stock advanced +0.31% Today — RQD Quant Desk Flash
KORU Medical Systems Inc. (KRMD) advanced +0.31% to $3.23, trading at 10% of its 52-week range ($2.86 – $6.61). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 10% of its 52-week range ($2.86 – $6.61) with RSI-14 at 42.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.6% around $3.23 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 62.3% gross margin and $462405 annual free cash flow.
Live KRMD Headlines & Catalysts
CATALYSTReuters • 4h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
CATALYSTReuters • 6h ago
Bank of England poised to raise rates but may push back on bets for more - ReutersBank of England poised to raise rates but may push back on bets for more Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 7h ago
Oil prices ease 3% on optimism for Qatari-led talks on ending Iran war - ReutersOil prices ease 3% on optimism for Qatari-led talks on ending Iran war Reuters
MARKET WIREReuters • 8h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 10h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 12h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRMD)
- ✓Walkthrough of KRMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.05%📐 HORIZONTAL RANGE
2026-10-30O $3.24H $3.24L $2.99C $3.23VOL 165.2K
RES: $4.80SUP: $2.67SMA50: $3.13SMA200: $4.02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on KRMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KRMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRMD)
Health Care Rank #382 of 1016
⚔️ LUNG vs KRMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KRMD vs. LUNG, SKYA, STIM, PYPD)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, KORU Medical Systems Inc. (KRMD) ranks #382 by composite RQD confidence (48/100, grade D) and #610 by equity capitalization ($149.1M). Within this direct 5-issuer industry benchmark cohort, KRMD leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. KRMD currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KRMD
ACTIVE
KORU Medical Systems Inc. | D | 48/100 | — | 62.3% | -28.7% | +0.31% | $149.1M | Benchmark Subject |
| LUNG Pulmonx Corporation | D- | 38/100 | — | 74.2% | -35.0% | +25.60% | $135.9M | /lung-vs-krmd → |
| SKYA SkyAI Inc. | D- | 36/100 | — | -30.0% | -35.0% | -0.68% | $126.7M | /skya-vs-krmd → |
| STIM Neuronetics Inc. | E | 31/100 | — | 48.5% | -35.0% | +5.31% | $181.3M | /stim-vs-krmd → |
| PYPD PolyPid Ltd. | E | 33/100 | — | — | -35.0% | -3.29% | $113.5M | /pypd-vs-krmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000704440In its most recent audited fiscal period (FY2025, filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported GAAP revenue of $41.1M (+22.2% vs. FY2024 revenue of $33.6M , and +44.2% cumulative change since FY2023) , GAAP net income of -$2.6M, operating cash flow of $462.4K, and free cash flow of $462.4K (+244.6% YoY). On the balance sheet, KRMD closed FY2025 with $28.2M in total assets against $0 in total debt (Altman Z-Score: 8.05, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $41.1M | -$2.6M | $462.4K | $462.4K | $28.2M | — |
| FY2024 (FY) | 2024-12-31 | $33.6M | -$6.1M | -$319.7K | -$319.7K | $27.2M | — |
| FY2023 (FY) | 2023-12-31 | $28.5M | -$13.7M | -$4.9M | -$4.9M | — | — |
3. KRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $3.23 (+0.31% 1D, market cap $149.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, KRMD ranks #382 in composite RQD confidence.
How does KRMD compare to LUNG and SKYA in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $135.9M) and SKYA (SkyAI Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KRMD?
Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KRMD trading relative to its 50-day, 200-day, and 52-week technical levels?
KRMD last traded at $3.23 (+0.31% on volume of 84,326 shares), positioning the stock +3.19% above its 50-day simple moving average ($3.13) and -19.65% below its 200-day simple moving average ($4.02). Across its 52-week range of $2.86 to $6.61, KRMD sits at the 9.9% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($2.92 to $3.54).
KRMD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is KRMD stock moving today?
Why KRMD Stock advanced +0.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.